Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:SMMT News 19 October 2025 - 14 January 2026

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK shares rose about 0.4% in early London trading after Summit Therapeutics announced a clinical trial collaboration to test ivonescimab with GSK’s experimental B7-H3 cancer drug. Patient dosing is expected to begin in mid-2026. GSK will report full-year results on Feb. 4. Senior managers recently acquired small amounts of GSK shares through company plans.
14 January 2026
···
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics shares fell 11% to $17.46 Monday after announcing a U.S. FDA biologics license application for its lung cancer drug ivonescimab. The company also disclosed a clinical trial collaboration with GSK to test a combination regimen in solid tumors. Investors are watching for the FDA’s next procedural step and updates from the J.P. Morgan Healthcare Conference.
12 January 2026
·
Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Dyne Therapeutics shares fell 16.9% to $18.44 after announcing a $300 million stock offering. SLM Corp dropped 15%, Kontoor Brands slid 9.5%, and Waystar Holding lost 8.4%. Major indexes were little changed as investors awaited the Federal Reserve’s interest-rate decision. The U.S. 10-year Treasury yield hovered near 4.19%.
10 December 2025
···········
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics shares traded at $17–18 on December 9, 2025, near the low end of their 52-week range of $15.55 to $36.91. The company’s lung cancer drug ivonescimab recently outperformed Keytruda in a limited trial, drawing attention but also regulatory questions. Summit granted inducement stock options to new hires on December 5. The company’s market cap stands near $13–14 billion.
9 December 2025
·
Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

SMMT Stock’s Wild Ride in 2025 Summit Therapeutics’ share price has been on a roller-coaster ride this year. After a steady climb through late summer, SMMT spiked above $25 intraday in mid-October, then pulled back to end last week just under $21 ts2.tech. The stock fell 4.5% on Friday, Oct. 17 alone ts2.tech as traders braced for the upcoming data presentation and earnings call. Even after that dip, Summit shares remain up solidly in 2025 (low double-digit percent gains) – roughly in line with the broader biotech sector (the SPDR S&P Biotech ETF is ~+20% YTD) ts2.tech. These dramatic swings
20 October 2025
·
Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

What to Know Before Markets Open on October 20, 2025 SMMT’s Wild Stock Ride in 2025 Summit Therapeutics’ share price has experienced extreme swings this year. After a steady climb through late summer, SMMT spiked to an intraday high above $25 on Oct. 13, 2025, before pulling back to end the week just under $21stockanalysis.com. The stock fell 4.5% on Friday (Oct. 17) alonestockanalysis.com, capping a choppy few days as traders braced for the ESMO conference and earnings. Despite the recent dip, Summit’s stock is still up double-digits in 2025, roughly in line with the broader biotech sector (the SPDR
19 October 2025
·

Stock Market Today

RELX share price slides again on AI worries; what to watch ahead of Feb 12 results

RELX share price slides again on AI worries; what to watch ahead of Feb 12 results

8 February 2026
RELX shares fell 4.6% to 2,145p on Friday, near a 52-week low, despite the FTSE 100 closing higher. The company disclosed a new buyback of 465,361 shares on Feb. 6 and has repurchased over 8.8 million shares since Jan. 2. Investors await RELX’s full-year 2025 results on Feb. 12 amid concerns over AI’s impact on its core business.
Glencore shares steady after Rio walks away — what to watch before Monday’s trade

Glencore shares steady after Rio walks away — what to watch before Monday’s trade

8 February 2026
Glencore shares closed up 0.6% at 478.10 pence Friday after Rio Tinto ended merger talks, issuing a “no intention to bid” statement. Glencore’s board rejected the proposed deal terms, citing concerns over valuation and governance. Attention now turns to possible asset sales, including its $5 billion Kazzinc stake, ahead of Glencore’s annual results on Feb. 18.
Go toTop